Zurcher Kantonalbank (Zurich Cantonalbank) Madrigal Pharmaceuticals, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 2,442 shares of MDGL stock, worth $717,068. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,442

Previous 2,442 -0.0%

Holding current value

$717,068

Previous $518,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$212.22 - $292.96 $424 - $585	-2 Reduced 0.08%	2,442 $518,000
Q2 2024 Jul 29, 2024	BUY	$193.33 - $291.99 $74,818 - $113,000	387 Added 18.81%	2,444 $684,000
Q1 2024 Apr 25, 2024	BUY	$171.37 - $283.23 $5,483 - $9,063	32 Added 1.58%	2,057 $549,000
Q4 2023 Jan 30, 2024	SELL	$120.4 - $237.13 $1,685 - $3,319	-14 Reduced 0.69%	2,025 $468,000
Q3 2023 Oct 25, 2023	BUY	$146.04 - $225.78 $41,475 - $64,121	284 Added 16.18%	2,039 $297,000
Q2 2023 Aug 07, 2023	BUY	$203.88 - $312.0 $24,873 - $38,064	122 Added 7.47%	1,755 $405,000
Q1 2023 May 08, 2023	BUY	$231.06 - $307.08 $21,719 - $28,865	94 Added 6.11%	1,633 $395,000
Q4 2022 Feb 01, 2023	SELL	$58.39 - $296.54 $3,153 - $16,013	-54 Reduced 3.39%	1,539 $446,000
Q2 2022 Aug 09, 2022	SELL	$58.04 - $100.2 $1,915 - $3,306	-33 Reduced 2.03%	1,593 $114,000
Q1 2022 Apr 21, 2022	BUY	$55.89 - $101.89 $20,511 - $37,393	367 Added 29.15%	1,626 $160,000
Q2 2020 Jul 28, 2020	BUY	$60.13 - $125.71 $45,518 - $95,162	757 Added 150.8%	1,259 $143,000
Q2 2018 Aug 06, 2018	BUY	$101.55 - $313.9 $50,978 - $157,577	502 New	502 $140,000

Others Institutions Holding MDGL

# of Institutions

295

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.02B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Madrigal Pharmaceuticals, Inc. Transaction History